Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04569747 · ClinicalTrials.gov registry record · Phase 2
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
A Phase 2 study of Breast Cancer and HER2-positive Breast Cancer, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 375
- Enrollment target
- 20
- Study locations
NCT04569747 is a Phase 2 study of Breast Cancer and HER2-positive Breast Cancer that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 375 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT04569747, a Phase 2 study of Breast Cancer and HER2-positive Breast Cancer, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 375 participants
- Enrollment target
- 20
- Study locations
Study Summary
This research study is studying a combination of HER2-directed therapies (trastuzumab and pertuzumab) and hormonal therapy as a treatment after surgery for hormone receptor positive breast cancer. The study drugs involved in this study are: * A combination of trastuzumab and pertuzumab given as an injection under the skin (PHESGO) * Hormonal (endocrine) Treatment
Conditions Studied
Interventions
- COMBINATION_PRODUCT Pertuzumab+TRASTUZUMAB
- DRUG ADJUVANT ENDOCRINE THERAPY
Study Locations (20)
Massachusetts
- Dana Farber Cancer Institite - Boston
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Brigham Cancer Center - Foxborough - Foxborough
- Cape Cod Healthcare Center - Hyannis
- Dana-Farber at Milford - Milford
- Dana-Farber at South Shore Hospital - Weymouth
Georgia
- Winship Cancer Institute at Emory University Hospital Midtown - Atlanta
- Emory University - Winship Cancer Institute - Atlanta
- Winship Cancer Institute at Emory Saint Joseph's Hospital - Atlanta
Indiana
- Indiana University Health Schwarz Cancer Center - Indianapolis
- Indiana University Health - Melvin and Bren Simon Cancer Center - Indianapolis
- Indiana University Sidney and Lois Eskenazi Hospital - Indianapolis
New York
- New York University Langone Hospital -Brooklyn - Brooklyn
- New York University Langone Hospital - Long Island - Mineola
- New York University Langone Health - New York
Connecticut
- Stamford Hospital - Stamford
Florida
- University of Miami- Sylvester Comprehensive Cancer Center - Miami
Illinois
- University of Chicago Medical Center - Chicago
Maine
- Eastern Maine Medical Center (Northern Light) - Brewer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 375 participants |
| Start Date | 2021-01-11 |
| Est. Completion | 2030-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04569747
The ClinicalTrials.gov registry entry for NCT04569747 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 375 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (87% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pertuzumab+TRASTUZUMAB is the first listed.
NCT04569747 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Massachusetts, Georgia, Indiana.
Frequently Asked Questions
What is clinical trial NCT04569747 about?
NCT04569747 is a clinical study titled "A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer". This research study is studying a combination of HER2-directed therapies (trastuzumab and pertuzumab) and hormonal therapy as a treatment after surgery for hormone receptor positive breast cancer. The study drugs involved in this study are: * A combination of trastuzumab and pertuzumab given as an...
What is the current status of trial NCT04569747?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 375 participants. The study started on 2021-01-11. Estimated completion is 2030-09-01.
What conditions does trial NCT04569747 study?
This clinical trial studies the following conditions: Breast Cancer, HER2-positive Breast Cancer, Hormone Receptor-Positive Breast Cancer, Node Negative Breast Cancer, Invasive Carcinoma of the Breast.
What interventions are being tested in trial NCT04569747?
The interventions under investigation include: Pertuzumab+TRASTUZUMAB (COMBINATION_PRODUCT), ADJUVANT ENDOCRINE THERAPY (DRUG).
Who is sponsoring clinical trial NCT04569747?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04569747 being conducted?
This trial has 20 study locations across Connecticut, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.